Literature DB >> 16189808

Estimation of prevalence and incidence based on occurrence of health-related events.

Henrik Støvring1, Werner Vach.   

Abstract

A new method for estimating incidence and prevalence is developed, which only requires observation of occurrence of health-related events within a given time window. Occurrence data are often easy to collect but estimating incidence and prevalence of a disease from such data is non-trivial, since the true disease status is not directly observed for all at the beginning of the study period. Our method for overcoming this problem is based on an idea first presented in 'The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization' (Epidemiology 1997; 8:666-670). Their fundamental idea is to analyse the waiting time from start of the window to the first event of each individual, and we formalize this by establishing a parametric likelihood which allows ordinary maximum likelihood analysis and explicit modelling of censoring. The developed method is used to analyse incidence and prevalence of hypertension in a Danish cohort of 70+-year-olds. A simulation study on the finite sample properties of the method is reported, which indicates that the method gives a quite robust and cost-effective alternative to ordinary surveys and follow-up studies for estimating incidence and prevalence. 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 16189808     DOI: 10.1002/sim.2142

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model.

Authors:  Helle Wallach Kildemoes; Henrik Støvring; Morten Andersen
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

2.  A new likelihood model for analyses of pharmacoepidemiologic case-control studies which avoids decision rules for determining latent exposure status.

Authors:  Henrik Støvring; Anton Pottegård; Jesper Hallas
Journal:  BMC Med Res Methodol       Date:  2021-07-08       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.